{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:52:01Z","timestamp":1771995121452,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11606-021-07114-8","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T20:08:28Z","timestamp":1632168508000},"page":"2982-2990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness and Safety of Dabigatran in Atrial Fibrillation Patients with Severe Obesity: a Real-World Retrospective Cohort Study"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7072-9679","authenticated-orcid":false,"given":"Cheng-Wei","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaejin","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Sum","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"issue":"2","key":"7114_CR1","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151. doi:https:\/\/doi.org\/10.1161\/CIR.0000000000000665","journal-title":"Circulation."},{"issue":"12","key":"7114_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007;146(12):857. doi:https:\/\/doi.org\/10.7326\/0003-4819-146-12-200706190-00007","journal-title":"Ann Intern Med."},{"issue":"10","key":"7114_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi:https:\/\/doi.org\/10.1056\/NEJMoa1009638","journal-title":"N Engl J Med."},{"issue":"11","key":"7114_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. doi:https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med."},{"issue":"12","key":"7114_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi:https:\/\/doi.org\/10.1056\/NEJMoa0905561","journal-title":"N Engl J Med."},{"issue":"22","key":"7114_CR6","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1161\/CIRCULATIONAHA.114.010426","volume":"130","author":"RK Wadhera","year":"2014","unstructured":"Wadhera RK, Russell CE, Piazza G. Warfarin versus novel oral anticoagulants: How to choose? Circulation. 2014;130(22):e194. doi:https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.010426","journal-title":"Circulation."},{"key":"7114_CR7","doi-asserted-by":"publisher","unstructured":"Perreault S, Denus S de, White-Guay B, et al. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Pharmacother J Hum Pharmacol Drug Ther. 2020;40(1):40-54. doi:https:\/\/doi.org\/10.1002\/PHAR.2350","DOI":"10.1002\/PHAR.2350"},{"issue":"8","key":"7114_CR8","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s11606-020-05904-0","volume":"35","author":"M Colacci","year":"2020","unstructured":"Colacci M, Tseng EK, Sacks CA, Fralick M. Oral Anticoagulant Utilization in the United States and United Kingdom. J Gen Intern Med. 2020;35(8):2505-2507. doi:https:\/\/doi.org\/10.1007\/s11606-020-05904-0","journal-title":"J Gen Intern Med."},{"key":"7114_CR9","doi-asserted-by":"publisher","unstructured":"Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300-1305.e2. https:\/\/doi.org\/10.1016\/j.amjmed.2015.05.044","DOI":"10.1016\/j.amjmed.2015.05.044"},{"issue":"10264","key":"7114_CR10","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","volume":"396","author":"N Chan","year":"2020","unstructured":"Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020;396(10264):1767-1776. doi:https:\/\/doi.org\/10.1016\/S0140-6736(20)32439-9","journal-title":"Lancet."},{"issue":"6","key":"7114_CR11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jth.13323","volume":"14","author":"K Martin","year":"2016","unstructured":"Martin K, Beyer-Westendorf J, Davidson BL, Huisman M V., Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308-1313. doi:https:\/\/doi.org\/10.1111\/jth.13323","journal-title":"J Thromb Haemost."},{"issue":"3","key":"7114_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jacep.2015.12.001","volume":"2","author":"A Pandey","year":"2016","unstructured":"Pandey A, Gersh BJ, McGuire DK, et al. Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. JACC Clin Electrophysiol. 2016;2(3):355-363. doi:https:\/\/doi.org\/10.1016\/j.jacep.2015.12.001","journal-title":"JACC Clin Electrophysiol."},{"key":"7114_CR13","doi-asserted-by":"publisher","unstructured":"Barakat AF, Jain S, Masri A, et al. Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories. JACC Clin Electrophysiol. Published online March 31, 2021. doi:https:\/\/doi.org\/10.1016\/j.jacep.2021.02.002","DOI":"10.1016\/j.jacep.2021.02.002"},{"key":"7114_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.thromres.2020.04.015","volume":"192","author":"T Patil","year":"2020","unstructured":"Patil T, Lebrecht M. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. Thromb Res. 2020;192:124-130. doi:https:\/\/doi.org\/10.1016\/j.thromres.2020.04.015","journal-title":"Thromb Res."},{"key":"7114_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijcard.2019.10.035","volume":"301","author":"M Lucijanic","year":"2020","unstructured":"Lucijanic M, Jurin I, Jurin H, et al. Patients with higher body mass index treated with direct \/ novel oral anticoagulants (DOAC \/ NOAC) for atrial fibrillation experience worse clinical outcomes. Int J Cardiol. 2020;301:90-95. doi:https:\/\/doi.org\/10.1016\/j.ijcard.2019.10.035","journal-title":"Int J Cardiol."},{"key":"7114_CR16","doi-asserted-by":"publisher","unstructured":"Kalani C, Awudi E, Alexander T, Udeani G, Surani S. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients. Hosp Pract (1995). 2019;47(4):181-185. https:\/\/doi.org\/10.1080\/21548331.2019.1674586","DOI":"10.1080\/21548331.2019.1674586"},{"key":"7114_CR17","doi-asserted-by":"publisher","unstructured":"Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study. J Clin Med 2020, Vol 9, Page 1633. 2020;9(6):1633. https:\/\/doi.org\/10.3390\/JCM9061633","DOI":"10.3390\/JCM9061633"},{"key":"7114_CR18","doi-asserted-by":"publisher","unstructured":"Briasoulis A, Mentias A, Mazur A, Alvarez P, Leira EC, Sarrazin MSV. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation. Cardiovasc Drugs Ther 2021 352. 2021;35(2):261-272. https:\/\/doi.org\/10.1007\/S10557-020-07126-2","DOI":"10.1007\/S10557-020-07126-2"},{"key":"7114_CR19","doi-asserted-by":"publisher","unstructured":"Brar T, Chua D. Direct Oral Anticoagulant Choice for Stroke Prevention in Obese Patients with Atrial Fibrillation. Can J Cardiol. Published online April 15, 2021. doi:https:\/\/doi.org\/10.1016\/j.cjca.2021.04.004","DOI":"10.1016\/j.cjca.2021.04.004"},{"issue":"2","key":"7114_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1060028018796604","volume":"53","author":"K Kido","year":"2019","unstructured":"Kido K, Ngorsuraches S. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation. Ann Pharmacother. 2019;53(2):165-170. doi:https:\/\/doi.org\/10.1177\/1060028018796604","journal-title":"Ann Pharmacother."},{"issue":"2","key":"7114_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1055\/s-0040-1715834","volume":"121","author":"AC Martin","year":"2021","unstructured":"Martin AC, Thomas W, Mahir Z, et al. Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study. Thromb Haemost. 2021;121(2):224-233. doi:https:\/\/doi.org\/10.1055\/s-0040-1715834","journal-title":"Thromb Haemost."},{"issue":"11","key":"7114_CR22","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1177\/1060028020923584","volume":"54","author":"J Sebaaly","year":"2020","unstructured":"Sebaaly J, Kelley D. Direct Oral Anticoagulants in Obesity: An Updated Literature Review. Ann Pharmacother. 2020;54(11):1144-1158. doi:https:\/\/doi.org\/10.1177\/1060028020923584","journal-title":"Ann Pharmacother."},{"issue":"11","key":"7114_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/ajhp\/zxaa059","volume":"77","author":"K Covert","year":"2020","unstructured":"Covert K, Branam DL. Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. Am J Heal Pharm. 2020;77(11):865-876. doi:https:\/\/doi.org\/10.1093\/ajhp\/zxaa059","journal-title":"Am J Heal Pharm."},{"key":"7114_CR24","unstructured":"Fast facts | Kaiser Permanente. Accessed May 2, 2021. https:\/\/about.kaiserpermanente.org\/who-we-are\/fast-facts"},{"key":"7114_CR25","doi-asserted-by":"publisher","unstructured":"Koebnick C. Sociodemographic Characteristics of Members of a Large, Integrated Health Care System: Comparison with US Census Bureau Data. Perm J. Published online August 1, 2012:37-41. https:\/\/doi.org\/10.7812\/TPP\/12-031","DOI":"10.7812\/TPP\/12-031"},{"issue":"23","key":"7114_CR26","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1161\/CIR.0000000000000041","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of cardiology\/American heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014;130(23):e199-e267. doi:https:\/\/doi.org\/10.1161\/CIR.0000000000000041","journal-title":"Circulation."},{"issue":"12","key":"7114_CR27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.joca.2010.10.003","volume":"18","author":"JA Singh","year":"2010","unstructured":"Singh JA, Ayub S. Accuracy of VA databases for diagnoses of knee replacement and hip replacement. Osteoarthr Cartil. 2010;18(12):1639-1642. doi:https:\/\/doi.org\/10.1016\/j.joca.2010.10.003","journal-title":"Osteoarthr Cartil."},{"key":"7114_CR28","doi-asserted-by":"publisher","unstructured":"Lin KJ, Singer DE, Glynn RJ, et al. Prediction score for anticoagulation control quality among older adults. J Am Heart Assoc. 2017;6(10). https:\/\/doi.org\/10.1161\/JAHA.117.006814","DOI":"10.1161\/JAHA.117.006814"},{"issue":"5","key":"7114_CR29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest. 2010;138(5):1093-1100. doi:https:\/\/doi.org\/10.1378\/chest.10-0134","journal-title":"Chest."},{"issue":"2","key":"7114_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-272. doi:https:\/\/doi.org\/10.1378\/chest.09-1584","journal-title":"Chest."},{"issue":"11","key":"7114_CR31","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. doi:https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83","journal-title":"Med Care."},{"issue":"3","key":"7114_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1037\/a0019623","volume":"15","author":"VS Harder","year":"2010","unstructured":"Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods. 2010;15(3):234-249. doi:https:\/\/doi.org\/10.1037\/a0019623","journal-title":"Psychol Methods."},{"issue":"10","key":"7114_CR33","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1160\/TH16-03-0203","volume":"116","author":"J Carmo","year":"2017","unstructured":"Carmo J, Costa FM, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation. Thromb Haemost. 2017;116(10):754-763. doi:https:\/\/doi.org\/10.1160\/TH16-03-0203","journal-title":"Thromb Haemost."},{"issue":"2","key":"7114_CR34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1161\/CIRCOUTCOMES.115.002369","volume":"9","author":"RJ Romanelli","year":"2016","unstructured":"Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2016;9(2):126-134. doi:https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.115.002369","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"2","key":"7114_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","volume":"131","author":"DJ Graham","year":"2015","unstructured":"Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation. Circulation. 2015;131(2):157-164. doi:https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.012061","journal-title":"Circulation."},{"key":"7114_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.amjmed.2018.12.023","volume":"132","author":"DJ Graham","year":"2019","unstructured":"Graham DJ, Baro E, Zhang R, et al. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. Am J Med. 2019;132:596-604. doi:https:\/\/doi.org\/10.1016\/j.amjmed.2018.12.023","journal-title":"Am J Med."},{"key":"7114_CR37","doi-asserted-by":"publisher","unstructured":"Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6). https:\/\/doi.org\/10.1161\/JAHA.116.003725","DOI":"10.1161\/JAHA.116.003725"},{"issue":"22","key":"7114_CR38","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","volume":"61","author":"TB Larsen","year":"2013","unstructured":"Larsen TB, Rasmussen LH, Skj\u00f8th F, et al. Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol. 2013;61(22):2264-2273. doi:https:\/\/doi.org\/10.1016\/j.jacc.2013.03.020","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"7114_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/jamainternmed.2014.5398","volume":"175","author":"I Hernandez","year":"2015","unstructured":"Hernandez I, Baik SH, Pi\u00f1era A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18-24. doi:https:\/\/doi.org\/10.1001\/jamainternmed.2014.5398","journal-title":"JAMA Intern Med."},{"issue":"2","key":"7114_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/STROKEAHA.115.011476","volume":"47","author":"YH Chan","year":"2016","unstructured":"Chan YH, Yen KC, See LC, et al. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians with Nonvalvular Atrial Fibrillation. Stroke. 2016;47(2):441-449. doi:https:\/\/doi.org\/10.1161\/STROKEAHA.115.011476","journal-title":"Stroke."},{"issue":"6","key":"7114_CR41","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1160\/TH15-06-0453","volume":"114","author":"TC Villines","year":"2015","unstructured":"Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114(6):1290-1298. doi:https:\/\/doi.org\/10.1160\/TH15-06-0453","journal-title":"Thromb Haemost."},{"key":"7114_CR42","doi-asserted-by":"publisher","unstructured":"Burke JF, Sussman JB, Kent DM, Hayward RA. Three simple rules to ensure reasonably credible subgroup analyses. BMJ. 2015;351. doi:https:\/\/doi.org\/10.1136\/bmj.h5651","DOI":"10.1136\/bmj.h5651"},{"issue":"3","key":"7114_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.112.001139","volume":"128","author":"SJ Connolly","year":"2013","unstructured":"Connolly SJ, Wallentin L, Ezekowitz MD, et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013;128(3):237-243. doi:https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.001139","journal-title":"Circulation."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-07114-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-021-07114-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-07114-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:04:11Z","timestamp":1663632251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-021-07114-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["7114"],"URL":"https:\/\/doi.org\/10.1007\/s11606-021-07114-8","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"assertion":[{"value":"24 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}